← Human Trials & Peer-Reviewed Studies
Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors
Plain-language guide to PMID 11345366 (2001): randomized controlled trial study of Bradykinin in 25 patients.
Key Facts
- PMID
- 11345366
- Journal
- Journal of the American College of Cardiology
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Minai K et al. (7 authors)
- DOI
- 10.1016/s0735-1097(01)01202-5
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Bradykinin, published as a randomized controlled trial.
The goal of this study was to determine: 1) whether bradykinin (BK) directly stimulates tissue plasminogen activator (tPA) secretion in human coronary circulation, and 2) whether angiotensin-converting enzyme (ACE) inhibition favorably alters the fibrinolytic balance regulated by BK.
Who Took Part
The abstract describes 25 patients taking part.
The age groups tagged for this paper are middle-aged adults, both men and women.
Fifty-six patients with atypical chest pain were randomly assigned to two groups: 25 patients were treated with the ACE inhibitor enalapril (ACE inhibitor group), and 31 were not treated with ACE inhibitors (non-ACE inhibitor group).
Coronary blood flow (CBF) was evaluated by Doppler flow velocity measurement.
How the Study Was Run
The design is described as randomized.
Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blood samples were taken from the aorta (Ao) and the coronary sinus (CS).
What Was Measured
The subject headings attached to it are Acetylcholine, Analysis of Variance, Angiotensin-Converting Enzyme Inhibitors, Blood Flow Velocity, Bradykinin, Cardiac Catheterization and Chest Pain.
What This Means in Plain Language
The paper is a randomized study of Bradykinin in 25 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2001 (Journal of the American College of Cardiology), a journal based in United States.
More context: the Bradykinin compound page, all human trials.
Our Notes on the Compound
Bradykinin: A 9-amino-acid peptide that widens blood vessels and causes swelling; given in research studies of blood flow.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.